Glucagon-like peptide-1 (GLP-1) receptor agonists have become one of the most discussed classes of compounds in both scientific and popular discourse. Understanding the underlying biology — and the distinctions between different GLP-1 receptor agonists — requires a clear-eyed look at the mechanism of action and the research evidence.
What Is GLP-1?
GLP-1 is an incretin hormone secreted by L-cells in the small intestine in response to nutrient ingestion. Its primary physiological roles are to stimulate glucose-dependent insulin secretion from pancreatic β-cells, suppress glucagon secretion from α-cells, slow gastric emptying, and reduce appetite via central nervous system effects.
Native GLP-1 has a very short half-life in circulation (approximately 2 minutes) due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists are synthetic peptides that mimic the effects of GLP-1 but are resistant to DPP-4 degradation, giving them a much longer duration of action.
The GLP-1 Receptor
The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) expressed in the pancreas, brain, heart, kidney, and gastrointestinal tract. Activation of GLP-1R in the pancreas stimulates insulin secretion in a glucose-dependent manner — meaning that the insulinotropic effect only occurs when blood glucose is elevated, which reduces the risk of hypoglycaemia compared to other insulin secretagogues.
The glucose-dependent nature of GLP-1R-mediated insulin secretion is one of the key pharmacological advantages of GLP-1 receptor agonists over older classes of insulin secretagogues, which can cause hypoglycaemia even in the absence of elevated blood glucose.
Liraglutide, Semaglutide, and Tirzepatide
Liraglutide was the first long-acting GLP-1 receptor agonist to receive regulatory approval. It shares approximately 97% sequence homology with native GLP-1 and has a half-life of approximately 13 hours, enabling once-daily dosing. Semaglutide, a second-generation GLP-1 receptor agonist, has a half-life of approximately 7 days, enabling once-weekly dosing. Its greater potency and longer duration of action have made it the dominant compound in this class.
Tirzepatide represents a further evolution: it is a dual GIP/GLP-1 receptor agonist, meaning it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone with complementary effects to GLP-1. The dual agonism of tirzepatide has been shown in clinical trials to produce greater reductions in HbA1c and body weight than GLP-1 mono-agonism.
Research Context
In the research context, GLP-1 receptor agonists are used as tools to study the GLP-1 receptor signalling pathway, incretin biology, and the metabolic effects of GLP-1R activation. They are also used in animal models of obesity and type 2 diabetes to study the mechanisms underlying the metabolic improvements observed with GLP-1R agonism.
Liraglutide, Semaglutide, and Tirzepatide are available from The Bio Edit for laboratory and in-vitro research purposes only. These compounds are not for human or animal consumption.
Conclusion
GLP-1 receptor agonists represent a mechanistically well-characterised class of peptides with a robust clinical evidence base. Understanding the biology of GLP-1 signalling — and the distinctions between different receptor agonists — provides essential context for interpreting the research literature and for designing experiments that use these compounds as research tools.